Begin main content

Keytruda for Squamous NSCLC – Details

Project Number pCODR 10176
Brand Name Keytruda
Generic Name Pembrolizumab
Tumour Type Lung
Indication Squamous NSCLC
Funding Request For the treatment of patients with metastatic squamous NSCLC in combination with carboplatin and either paclitaxel or nab-paclitaxel, in adults with no prior systemic chemotherapy treatment for metastatic NSCLC
Review Status Pending
Pre Noc Submission
NOC Date
Manufacturer Merck Canada
Submitter Merck Canada
Submission Date (Target Date) February 8, 2019
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡ February 25, 2019
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.